Italia markets close in 3 hours 51 minutes

Mirati Therapeutics, Inc. (MRTX)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
225,46+2,05 (+0,92%)
Alla chiusura: 4:00PM EST
Accedi per pubblicare un messaggio.
  • J
    Jason Gustavo Esperado
    $AFMD conversation
    $AFMD should be currently worth at least double/triple to that of $MRTX considering AFM24 is independent of EGFR signaling and mutational status and not limited to just KRAS mutations.
  • W
    WhyNot
    $AGEN conversation
    $mrtx was under 3, 3 years ago. Now it's over 200 on good kras data for lung cancer. I had similar dreams stock price dreams for $agen when I made my first purchase in 2017. Now I just dream of $agen staying above $4 lol. God dammit.
  • p
    patrick
    SunTrust just released a note stating that a series of strong data catalysts&disruptive medicines being commercialized or entering the clinic they recommend investors being overweight biotech. Their recommendations are:

    $CRSP $BMRN $CBAY
    $EDIT $EXEL $INCY
    $MRTX
    $RARE $SAGE $SRPT $VKTX $WVE

    Our time is coming - just be patient.
  • A
    AIKIDO
    $VSTM should play catch up to $MRTX KRAS worth $3.8B and $AMGN , a nice partnership is welcome
  • K
    Kim
    $SRPT conversation
    From Michelle Solly:
    Keeping an eye on a new fund, launched in Aug 2019, Logos Global!

    The team is formerly of Farallon and Versant, with ~$400m AUM (from 13F)

    They had their first filing! Top positions:

    $MRTX (8.06%)
    $SRPT (7.19%)
    $ASND (6.17%)
    $AMRN (5.09%)
    $APLS (4.43%)
  • A
    AIKIDO
    VSTM massive upside coming its all about KRAS now HOT , check $MRTX and $AMGN
  • M
    Mango
    Array BioPharma Inc.
    An Update On Array: Moving Into A New Market https://seekingalpha.com/article/4238737?source=ansh $ARRY, $ASLN, $AZN, $LLY, $LOXO, $MRTX, $OPHLF
    Braftovi and Mektovi commercial revenue has grown 62.1% QoQ. Braftovi and Mektovi is approved and launched in Europe and recently approved in Japan. Substantial
    Braftovi and Mektovi commercial revenue has grown 62.1% QoQ. Braftovi and Mektovi is approved and launched in Europe and recently approved in Japan. Substantial
    seekingalpha.com
  • D
    David
    $MRTX conversation
    This equity analyst sees big things coming for $MRTX and others in 2019:
    "Deciphera’s  $DCPH Phase III top line reads out at ASCO, Mirati’s competitor Amgen (NASDAQ:$AMGN) will likely present clinical data on its KRAS inhibitor at ASCO and Mirati clinical data likely at ESMO, or European Society for Medical Oncology. Scientists have been trying for the last two to three decades to come up with a targeted KRAS inhibitor, and it finally looks like Mirati and Amgen have cracked the code. Any positive updates from Amgen will likely be read as positive for Mirati.BerGenBio has second-line lung cancer and second-line AML — acute myeloid leukemia — data at ASCO. Celyad $CYAD is also presenting mature Phase I data in AML and colorectal cancer, Neon $NTGN will be presenting 52-week mature data in melanoma and lung cancer at ASCO, and Forty Seven Inc. $FTSV will provide an update on mature Phase II data with 5F9 in relapse/refractory NHL."
    https://www.twst.com/interview/clinical-data-and-ma-serve-as-catalysts-in-2019
    Word count: 2,849 TWST: If you could, just start out by telling the readers what your coverage universe is. Dr. Roy: The focus of my coverage is disruptive technologies and is currently mostly focused on oncology. My coverage universe can be divided
    Word count: 2,849 TWST: If you could, just start out by telling the readers what your coverage universe is. Dr. Roy: The focus of my coverage is disruptive technologies and is currently mostly focused on oncology. My coverage universe can be divided
    www.twst.com
  • L
    Lucas A. Johnson
    $MRTX conversation
    Where can you find the best plays from across the markets? ExplosiveOTC consistently uncovers the hidden gems before they break out. www.explosiveotc.com
    ExplosiveOTC
    ExplosiveOTC
    www.explosiveotc.com
  • C
    Cfa
    It’s called a bioscam for a reason. $MRTX $NLNK $ANAB $AUPH $GALT $COOL $CARA $CNAT $MNKD $CALA and all other biotech scams will end up the same.
  • A
    AIKIDO
    VSTM it’s time to accumulate shares KRAS is huge look at $MRTX and $AMGN much bigger than $TRIL and $FTRV cd47
  • A
    AIKIDO
    Buying more here think will see $10 pretty soon $MRTX
  • A
    AIKIDO
    $MRTX still up 500% with no sales yet should move some to $AMRN and NBRV
  • C
    Cfa
    $MRNS $CARA $AUPH $SGMO $CNAT $CALA $MNKD $ANAB $MRTX $NLNK ALL THOSE biotech SCAMS will end up like $DCTH. Their chart will be down by 99% soon. Some in a year, some sooner some later. Remember 99% US small biotech companies are scams.
  • A
    AIKIDO
    Shorts negative report on $FGEN is burning now same will happen in $AMRN next week, like $MDGL $AALK $MRTX and $RETA booom, this sector is recovering
  • N
    No Short
    Mirati Therapeutics, Inc.
    going back up to 6.00
  • s
    smc
    $IDRA conversation
    One analyst is not happy at all with the recent data presented at ESMO by DVAX. However, he likes the IDRA's
    approach but still wants to see more confirmation of TILSO effect in the combo , means more data..

    Similar to $MRTX, $DVAX reports "responses that will not confirm" as well

    From a 21.4% listed ORR for the PD-1 refractory study, only half that will confirm for a true ITT ORR of 10%

    And according to the Swimmer plot for PD-1 naive melanoma, only 24/47 confirmed ORR = 51% ORR

    When the same analyst was asked why DVAX data he doesn't like, below was his reply which I don't understand ofcourse :-)

    -ECHO-301
    -ITT analysis
    -Abscopal effect
    -Single arm melanoma trials poorly predict randomized data (see https://meetinglibrary.asco.org/record/159087 )
    -ECHO-301
    -No dose response
    -ECHO-301
    -ECHO-301
    Meeting Library | Meeting Library
    meetinglibrary.asco.org
  • A
    AIKIDO
    KALA heavy insiders buying could rocket like $ALLK $MRTX $RETA $SGEN $ACAD $CLVS
  • C
    Cfa
    One of the most popular scam methods, release cancer study PR pump and dump, $OTIC $ZYNE $CARA. The next is $MRTX scam.
  • T
    Thelma
    Hi Just want to know why $mrtx dropped today